Compare OGN & DSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGN | DSL |
|---|---|---|
| Founded | 1923 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2020 | 2013 |
| Metric | OGN | DSL |
|---|---|---|
| Price | $13.75 | $10.66 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.40 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 503.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | 0.60% | ★ 11.95% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $6,216,000,000.00 | N/A |
| Revenue This Year | $0.45 | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | $14.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.69 | $10.49 |
| 52 Week High | $13.76 | $12.67 |
| Indicator | OGN | DSL |
|---|---|---|
| Relative Strength Index (RSI) | 72.40 | 43.13 |
| Support Level | $13.46 | $10.53 |
| Resistance Level | N/A | $11.02 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 93.18 | 18.04 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.